Published in J Pharmacol Exp Ther on February 01, 2001
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med (2003) 3.13
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
The posttranslational processing of prelamin A and disease. Annu Rev Genomics Hum Genet (2009) 1.81
A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol (2006) 1.67
Development of bisphosphonates. Breast Cancer Res (2001) 1.63
Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer (2010) 1.61
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Tumour macrophages as potential targets of bisphosphonates. J Transl Med (2011) 1.53
The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol (2005) 1.49
The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol (2010) 1.44
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int (2008) 1.42
Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone (2010) 1.41
Biosynthesis of terpenes: studies on 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase. Proc Natl Acad Sci U S A (2002) 1.38
Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther (2013) 1.29
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer (2006) 1.22
Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis (2014) 1.22
Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data. J Med Chem (2008) 1.21
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases (2011) 1.11
Bone remodeling markers: so easy to measure, so difficult to interpret. Osteoporos Int (2015) 1.08
The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer (2002) 1.05
The acidocalcisome as a target for chemotherapeutic agents in protozoan parasites. Curr Pharm Des (2008) 1.05
Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem (2011) 1.03
Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from Plasmodium parasites. J Biol Chem (2010) 1.03
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (2010) 1.03
Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest (2002) 1.01
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone (2009) 0.99
Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J Immunol (2011) 0.97
The enhancement of radiosensitivity in human esophageal squamous cell carcinoma cells by zoledronic acid and its potential mechanism. Cytotechnology (2013) 0.97
Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res (2001) 0.94
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res (2008) 0.92
Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases. Proteins (2008) 0.92
[Bisphosphonate-associated osteonecrosis of the jaw]. Mund Kiefer Gesichtschir (2006) 0.92
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer (2006) 0.91
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int (2008) 0.91
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer (2010) 0.91
Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Bone (2014) 0.90
Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A (2008) 0.90
A review of minodronic acid hydrate for the treatment of osteoporosis. Clin Interv Aging (2013) 0.89
Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab (2011) 0.89
Acute effects of intravenous administration of pamidronate in patients with osteoporosis. J Korean Med Sci (2010) 0.88
Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases. BMC Cancer (2009) 0.88
Effect of risedronate on bone in renal transplant recipients. J Am Soc Nephrol (2012) 0.88
The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro. Head Face Med (2010) 0.88
Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase. Beilstein J Org Chem (2014) 0.87
Bisphosphonate treatment in the oim mouse model alters bone modeling during growth. J Biomech (2008) 0.87
Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leuk Res (2009) 0.87
Human isoprenoid synthase enzymes as therapeutic targets. Front Chem (2014) 0.86
Bisphosphonates pathway. Pharmacogenet Genomics (2011) 0.86
Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell (2006) 0.86
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int (2011) 0.86
The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. Odontology (2011) 0.86
Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis. J Bone Miner Metab (2015) 0.85
Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease. Mol Neurobiol (2012) 0.85
Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag (2015) 0.85
Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin Exp Metastasis (2012) 0.85
Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J Bone Miner Metab (2008) 0.85
Design, synthesis, calorimetry, and crystallographic analysis of 2-alkylaminoethyl-1,1-bisphosphonates as inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. J Med Chem (2012) 0.84
CONNEXIN 43 AND BONE: NOT JUST A GAP JUNCTION PROTEIN. Actual osteol (2011) 0.84
Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. J Bone Miner Res (2013) 0.84
1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase. Org Biomol Chem (2012) 0.84
The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta. Orthop Rev (Pavia) (2012) 0.84
Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways. Arch Biochem Biophys (2012) 0.84
Protein farnesylation and disease. J Inherit Metab Dis (2012) 0.83
Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol (2011) 0.82
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging (2009) 0.82
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer (2004) 0.82
Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures. Mol Pharm (2011) 0.82
The susceptive alendronate-treatment timing and dosage for osteogenesis enhancement in human bone marrow-derived stem cells. PLoS One (2014) 0.81
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
Bisphosphonates and cancer: what opportunities from nanotechnology? J Drug Deliv (2013) 0.81
Alendronate preserves femoral head shape and height/length ratios in an experimental rat model: A computer-assisted analysis. Indian J Orthop (2009) 0.81
Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer (2007) 0.80
Ceramides: a potential therapeutic target in pulmonary emphysema. Respir Res (2013) 0.80
Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells. Oncol Lett (2012) 0.79
Surface immobilized zoledronate improves screw fixation in rat bone: a new method for the coating of metal implants. J Mater Sci Mater Med (2010) 0.79
CCN1, a candidate target for zoledronic acid treatment in breast cancer. Mol Cancer Ther (2011) 0.79
Neonatal hypercalcemia secondary to subcutaneous fat necrosis successfully treated with pamidronate: a case series and literature review. AJP Rep (2014) 0.79
Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management. Ther Adv Musculoskelet Dis (2009) 0.79
A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton. Small GTPases (2015) 0.79
Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010). Expert Opin Ther Pat (2011) 0.79
Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy. Biomed Rep (2013) 0.79
Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res (2015) 0.78
Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. Oncotarget (2015) 0.78
Metabolically regulated endoplasmic reticulum-associated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase: evidence for requirement of a geranylgeranylated protein. J Biol Chem (2011) 0.78
Impaired prenylation of Rab GTPases in the gunmetal mouse causes defects in bone cell function. Small GTPases (2011) 0.78
Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett (2015) 0.78
The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. Eur J Drug Metab Pharmacokinet (2014) 0.78
Ras Isoprenylation and pAkt Inhibition by Zoledronic Acid and Fluvastatin Enhances Paclitaxel Activity in T24 Bladder Cancer Cells. Cancers (Basel) (2011) 0.78
Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats. Clin Exp Metastasis (2007) 0.78
Flare-up of hand osteoarthritis caused by zoledronic acid infusion. Osteoporos Int (2009) 0.78
Induction of creatine kinase release from cultured osteoclasts via the pharmacological action of aminobisphosphonates. Springerplus (2015) 0.77
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag (2010) 0.77
Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study. Support Care Cancer (2009) 0.77
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Amino acid sequence of the human fibronectin receptor. J Cell Biol (1987) 4.08
A primary genetic map of chromosome 13q. Am J Hum Genet (1986) 4.01
Creating isoprenoid diversity. Science (1997) 3.78
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res (1998) 3.65
DNA-based immunization by in vivo transfection of dendritic cells. Nat Med (1996) 3.62
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
Construction of the mycoplasma evolutionary tree from 5S rRNA sequence data. Proc Natl Acad Sci U S A (1985) 3.38
Purification and properties of rat liver microsomal stearyl coenzyme A desaturase. Proc Natl Acad Sci U S A (1974) 3.18
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) 3.13
Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-A resolution. Biochemistry (1994) 3.10
Cognitive effects of corticosteroids. Am J Psychiatry (1990) 2.85
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Bisphosphonates: from the laboratory to the clinic and back again. Bone (1999) 2.55
Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sci U S A (1993) 2.44
Anticodon and acceptor stem nucleotides in tRNA(Gln) are major recognition elements for E. coli glutaminyl-tRNA synthetase. Nature (1991) 2.39
Comparison of circumsporozoite proteins from avian and mammalian malarias: biological and phylogenetic implications. Proc Natl Acad Sci U S A (1996) 2.35
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res (2000) 2.32
Synthesis of allylic and homoallylic isoprenoid pyrophosphates. Methods Enzymol (1985) 2.18
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci U S A (1977) 2.16
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol (1997) 2.14
Regulation of product chain length by isoprenyl diphosphate synthases. Proc Natl Acad Sci U S A (1996) 2.13
Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med (1995) 2.06
The response of two contrasting limestone grasslands to simulated climate change. Science (2000) 2.06
Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein. Science (1990) 2.04
Isoprenyl diphosphate synthases: protein sequence comparisons, a phylogenetic tree, and predictions of secondary structure. Protein Sci (1994) 1.82
Nurses could halve GP workload. BMJ (1995) 1.81
Plasmodium: genus-conserved primers for species identification and quantitation. Exp Parasitol (1995) 1.81
Chain elongation in the isoprenoid biosynthetic pathway. Curr Opin Chem Biol (1997) 1.78
Reports of extraordinary fecundity in early California. Bull N Y Acad Med (1973) 1.74
Appearance and distribution of surface proteins of the human erythrocyte membrane. An electron microscope and immunochemical labeling study. J Cell Biol (1978) 1.73
Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res (1997) 1.72
The binding of cytochrome b 5 to liver microsomes. J Biol Chem (1972) 1.71
Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res (2000) 1.70
Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II. Proc Natl Acad Sci U S A (1994) 1.69
Escherichia coli open reading frame 696 is idi, a nonessential gene encoding isopentenyl diphosphate isomerase. J Bacteriol (1999) 1.64
Biodiversity in urban habitat patches. Sci Total Environ (2005) 1.58
Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res (2004) 1.57
The cytoplasmic ribosomal RNAs of Plasmodium spp. Parasitol Today (1995) 1.56
Isopentenyl diphosphate:dimethylallyl diphosphate isomerase. An improved purification of the enzyme and isolation of the gene from Saccharomyces cerevisiae. J Biol Chem (1989) 1.56
No consistent effect of plant diversity on productivity. Science (2000) 1.52
Inhibition of Plasmodium falciparum protein synthesis. Targeting the plastid-like organelle with thiostrepton. J Biol Chem (1997) 1.51
The Claviceps purpurea gene encoding dimethylallyltryptophan synthase, the committed step for ergot alkaloid biosynthesis. Biochem Biophys Res Commun (1995) 1.51
Lipid-protein interactions in the reconstitution of the microsomal reduced nicotinamide adenine dinucleotide-cytochrome b 5 reductase system. J Biol Chem (1973) 1.49
Farnesyl diphosphate synthetase. Molecular cloning, sequence, and expression of an essential gene from Saccharomyces cerevisiae. J Biol Chem (1989) 1.48
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol (1999) 1.48
Apparent dependence of interactions between cytochrome b5 and cytochrome b5 reductase upon translational diffusion in dimyristoyl lecithin liposomes. Proc Natl Acad Sci U S A (1975) 1.46
Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. Am J Cardiol (1998) 1.44
A Spiroplasma tRNA gene cluster. Isr J Med Sci (1984) 1.44
The crtE gene in Erwinia herbicola encodes geranylgeranyl diphosphate synthase. Proc Natl Acad Sci U S A (1992) 1.42
Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. Biochemistry (1999) 1.40
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res (1997) 1.39
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res (1998) 1.39
1H-15N NMR studies of Escherichia coli tRNA(Phe) from hisT mutants: a structural role for pseudouridine. Biochemistry (1991) 1.38
Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des (2010) 1.37
Genetic influence of the kidneys on blood pressure. Evidence from chronic renal homografts in rats with opposite predispositions to hypertension. Circ Res (1974) 1.37
Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res (1998) 1.36
Effects of site-directed mutagenesis of the highly conserved aspartate residues in domain II of farnesyl diphosphate synthase activity. J Biol Chem (1992) 1.35
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone (2001) 1.35
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Molecular mechanisms of action of bisphosphonates. Bone (1999) 1.33
Regulation and trafficking of three distinct 18 S ribosomal RNAs during development of the malaria parasite. J Mol Biol (1997) 1.33
E. coli MEP synthase: steady-state kinetic analysis and substrate binding. Biochemistry (2002) 1.32
Isopentenyl-diphosphate isomerase: inactivation of the enzyme with active-site-directed irreversible inhibitors and transition-state analogues. Biochemistry (1988) 1.32
Recognition of bases in Escherichia coli tRNA(Gln) by glutaminyl-tRNA synthetase: a complete identity set. EMBO J (1992) 1.31
The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum (2001) 1.31
Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int (1999) 1.31
Posttraumatic stress disorder and service utilization among urban mental health center clients. J Trauma Stress (1999) 1.31
The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res (1999) 1.30
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
Continuous fluorescence assay for protein prenyltransferases. Methods Enzymol (1995) 1.27
Endemic contamination of clinical specimens by Mycobacterium gordonae. Clin Infect Dis (2000) 1.27
15N-labeled Escherichia coli tRNAfMet, tRNAGlu, tRNATyr, and tRNAPhe. Double resonance and two-dimensional NMR of N1-labeled pseudouridine. J Biol Chem (1985) 1.27
Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev (1993) 1.25
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone (2003) 1.24
The CaaX proteases, Afc1p and Rce1p, have overlapping but distinct substrate specificities. Mol Cell Biol (2000) 1.22
Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem (2001) 1.22
Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. Bioconjug Chem (2008) 1.22
A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med (2000) 1.22
Pre-steady-state study of recombinant sesquiterpene cyclases. Biochemistry (1997) 1.22
Photoaffinity labeling of the Ah receptor. J Biol Chem (1986) 1.21
1-Deoxy-D-xylulose 5-phosphate synthase, the gene product of open reading frame (ORF) 2816 and ORF 2895 in Rhodobacter capsulatus. J Bacteriol (2001) 1.19
Studies with recombinant Saccharomyces cerevisiae CaaX prenyl protease Rce1p. Biochemistry (2000) 1.18
A mechanism for posttranslational modifications of proteins by yeast protein farnesyltransferase. Proc Natl Acad Sci U S A (1995) 1.18